Cognition Therapeutics Provides Biomarker1 Analysis Update from the Phase 2 ‘SHINE’ Study

November 25, 2024

DENVER, Colo., Nov 25, 2024 (247marketnews.com)- Cognition Therapeutics (NASDAQ: CGTX) provided a biomarker1 analysis update from the Phase 2 ‘SHINE’ study in mild-to-moderate Alzheimer’s disease, focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau2172. Several blood-based biomarker changes occurred in concert with a 95% slowing of cognitive decline as measured by ADAS-Cog11 in the same patients, providing further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological system.

Anthony O. Caggiano, MD, PhD, Cognition’s CMO and head of R&D, commented, “We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated with improvements in key indicators of brain cell function. This finding gives us confidence that CT1812 is having a disease-modifying effect.

“We expect to make a full presentation of these and other biomarker results at scientific conferences in 2025. In addition, we look forward to meeting with the FDA to review these compelling clinical and biomarker findings and aligning on a Phase 3 program design.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.